A study to understand cancer prevention through lifestyle and genetics

Connect for Cancer Prevention Study: A Prospective Cohort Study Within Integrated Healthcare Systems in the US

National Institutes of Health Clinical Center (CC) · NCT04609072

This study is trying to find out how lifestyle and genetics affect cancer risk by collecting health information from 200,000 adults aged 30 to 70 who have never had cancer.

Quick facts

Study typeObservational
Enrollment200000 (estimated)
Ages30 Years to 70 Years
SexAll
SponsorNational Institutes of Health Clinical Center (CC) (nih)
Locations10 sites (Denver, Colorado and 9 other locations)
Trial IDNCT04609072 on ClinicalTrials.gov

What this trial studies

The Connect for Cancer Prevention Study aims to investigate the causes of cancer by collecting data on lifestyle, genetics, and health history from participants. This observational cohort study will enroll 200,000 adults aged 30 to 70 who have never had cancer, utilizing modern digital technologies to gather repeated exposure information and biological specimens. Participants will be followed over time to identify factors influencing cancer risk and to establish a biorepository for future research. The study seeks to create a comprehensive resource for understanding cancer etiology, early detection, and survivorship.

Who should consider this trial

Good fit: Ideal candidates are adults aged 30 to 70 who receive healthcare from participating systems and have never been diagnosed with invasive cancer.

Not a fit: Patients with a history of invasive cancer (other than non-melanoma skin cancer) or known cognitive impairments may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to new insights and strategies for cancer prevention, potentially reducing the incidence of cancer.

How similar studies have performed: Other studies have shown success in using similar observational approaches to understand cancer risk factors, making this study a continuation of established research methodologies.

Eligibility criteria

Show full inclusion / exclusion criteria
* INCLUSION CRITERIA:

Due to the minimal risk nature of this protocol, all individuals interested and able to participate in Connect for Cancer Prevention, who meet the eligibility criteria at time of initial study invitation, will be able to participate. In order to be eligible to participate in this study, an individual must meet all of the following criteria:

* Patients or members of participating IHCS at the time of enrollment
* Age between 30 and 70 years old at study invitation

If an individual is determined to be ineligible at the time of enrollment due to age, the individual will be allowed to re-enroll at a later time once the recruit meets the age requirement. This includes recruits that did not meet the original age requirement of 40-65 years of age but now meet the updated age range of 30-70.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria at time of initial study invitation will be excluded from participation in this study:

* Individuals with a confirmed history of invasive cancer (other than non-melanoma skin cancer)
* Individuals with known cognitive impairment documented in their medical record

Where this trial is running

Denver, Colorado and 9 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Cancer, General Research Use, Risk Factors, medical conditions, Pathology, Blood, Urine, Natural History

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.